<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Estrone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00655</strong>&#160; (APRD00588)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion of adrostenedione. Estrone may be further metabolized to 16-alpha-hydroxyestrone, which may be reduced to estriol by estradiol dehydrogenase.</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00655/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00655/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00655.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00655.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00655.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00655.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00655.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00655">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>3-Hydroxy-1,3,5(10)-estratrien-17-one</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Estrona</td><td>Spanish</td><td>INN</td></tr><tr><td>Estrone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>INN, USAN</td></tr><tr><td>Estronum</td><td>Latin</td><td>INN</td></tr><tr><td>follicular hormone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Oestrone</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Estrone</td><td>Watson</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="mixtures"><thead><tr><th>Brand Name</th><th>Ingredients</th></tr></thead><tbody><tr><td>Cimicifuga Plex</td><td>Caulophyllum Thalictroides + Cimicifuga Racemosa + Copper + Cotton Plant + Estrone + Histamine Dihydrochloride + Hypothalamus + Magnesium Phosphate Dibasic + Pituitary Whole + Platinum + Sepia Officinalis L + Thyroid</td></tr></tbody></table></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/estrogens">Estrogens</a></li>
<li><a href="/mesh/anti-menopausal-agents">Anti-menopausal Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>53-16-7</td></tr><tr><th>Weight</th><td>Average: 270.3661<br>Monoisotopic: 270.161979948</td></tr><tr><th>Chemical Formula</th><td>C<sub>18</sub>H<sub>22</sub>O<sub>2</sub></td></tr><tr><th>InChI Key</th><td>DNXHEGUUPJUMQT-CBZIJGRNSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C18H22O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-16,19H,2,4,6-9H2,1H3/t14-,15-,16+,18+/m1/s1</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">(1S,10R,11S,15S)-5-hydroxy-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-trien-14-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">[H][C@@]12CCC(=O)[C@@]1(C)CC[C@]1([H])C3=C(CC[C@@]21[H])C=C(O)C=C3</div></td></tr><tr><th>Mass Spec</th><td><a href="/system/mass_specs/DB00655.gif?1265922773">show</a>(9.95 KB)</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Lipids</td></tr><tr><th>Class</th><td>Steroids and Steroid Derivatives</td></tr><tr><th>Subclass</th><td>Ketosteroids</td></tr><tr><th>Direct parent</th><td>Ketosteroids</td></tr><tr><th>Alternative parents</th><td>Hydroxysteroids; Phenanthrenes and Derivatives; Tetralins; Phenols and Derivatives; Ketones; Polyamines; Enols</td></tr><tr><th>Substituents</th><td>phenanthrene; tetralin; phenol derivative; benzene; ketone; polyamine; enol; carbonyl group</td></tr><tr><th>Classification description</th><td>This compound belongs to the ketosteroids. These are steroid derivatives comprising a ketone group attached to steroid skeleton.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For management of perimenopausal and postmenopausal symptoms.</td></tr><tr><th>Pharmacodynamics</th><td>Estrone, a synthetically prepared or naturally occurring steroidal estrogen obtained from pregnant equine urine, is the primary circulating estrogen after menopause. Estrone is naturally derived from the peripheral conversion of androstenedione by an aromatase enzyme found in adipose tissues and is converted to estradiol in peripheral tissues. The estrogenic potency of estrone is one third that of estradiol. Estropipate is piperazine-stabilized estrone sulfate. Estrone, and estropipate are used to treat abnormalities related to gonadotropin hormone dysfunction, vasomotor symptoms, atrophic vaginitis, and vulvar atrophy associated with menopause, and for the prevention of osteoporosis due to estrogen deficiency.</td></tr><tr><th>Mechanism of action</th><td>Estrogens enter the cells of responsive tissues (e.g. female organs, breasts, hypothalamus, pituitary) where they interact with estrogen receptors. Hormone-bound estrogen receptors dimerize, translocate to the nucleus of cells and bind to estrogen response elements (ERE) of genes. Binding to ERE alters the transcription rate of affected genes. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) release from the anterior pituitary.</td></tr><tr><th>Absorption</th><td>43%</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>&gt; 95%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Estrone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00248">2-hydroxyestrone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/249">Details</a></td></tr><tr><td>Estrone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00332">4-hydroxyestrone</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/333">Details</a></td></tr><tr><td>Estrone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00530">Estrone sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/545">Details</a></td></tr><tr><td>Estrone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00569">Estrone glucuronide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/587">Details</a></td></tr><tr><td>Estrone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00615">2-Hydroxyestrone sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/634">Details</a></td></tr><tr><td>Estrone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00616">4-Hydroxyestrone sulfate</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/635">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>19 hours</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Symptoms of overdose include nausea and vomiting. Estrogen related side effects include nausea, breast tenderness, fluid retention and edema, headaches and/or migraines, chloasma and poor contact lens fit. Estrogen hormone deficiency is associated with breakthrough bleeding, hypomenorrhea, irritability, depression and menopausal symptoms. Withdrawal bleeds may occur in females.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9529</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8934</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.6001</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.9066</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8882</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.73</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.6624</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.729</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.9017</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9353</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9599</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8954</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8681</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9268
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8917
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.9717
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          1.9267 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.8711
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.5459
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Wyeth ayerst laboratories</li>
<li>Watson laboratories inc</li>
<li>Parkedale pharmaceuticals inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li>Carlisle Laboratories Inc.</li>
<li><a href="http://www.clintpharmaceuticals.com">Clint Pharmaceutical Inc.</a></li>
<li>Consolidated Midland Corp.</li>
<li><a href="http://www.gallipot.com">Gallipot</a></li>
<li>Martin Surgical Supply</li>
<li><a href="http://www.medisca.com">Medisca Inc.</a></li>
<li><a href="http://www.meritpharm.com">Merit Pharmaceuticals</a></li>
<li>National Pharmaceuticals</li>
<li>North America Genescience LLC</li>
<li>Primedics Laboratories</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Cream</td><td>Intravaginal</td><td>1 mg/g</td></tr><tr><td>Liquid</td><td>Oral</td><td></td></tr><tr><td>Solution / drops</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><ul><li><a data-no-turbolink="true" href="/spectra/spectra/c_ms/271">Gas-MS Spectrum</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/218">MS/MS Spectrum Quattro_QQQ 10</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/219">MS/MS Spectrum Quattro_QQQ 25</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/220">MS/MS Spectrum Quattro_QQQ 40</a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/3054">MS/MS Spectrum EI-B (HITACHI M-80) </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/7682">MS/MS Spectrum GC-MS </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/7704">MS/MS Spectrum GC-MS </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/ms_ms/7706">MS/MS Spectrum GC-MS </a></li>
<li><a data-no-turbolink="true" href="/spectra/spectra/nmr_two_d/1167">[1H,13C] 2D NMR Spectrum</a></li></ul></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01320">Fosphenytoin</a></td><td>The enzyme inducer, fosphenytoin, decreases the effect of the hormone agent, estrone.</td></tr><tr><td><a href="/drugs/DB00400">Griseofulvin</a></td><td>The enzyme inducer, griseofulvin, decreases the effect of the hormone agent, estrone.</td></tr><tr><td><a href="/drugs/DB01174">Phenobarbital</a></td><td>The enzyme inducer, phenobarbital, decreases the effect of the hormone agent, estrone.</td></tr><tr><td><a href="/drugs/DB00252">Phenytoin</a></td><td>The enzyme inducer, phenytoin, decreases the effect of the hormone agent, estrone.</td></tr><tr><td><a href="/drugs/DB00860">Prednisolone</a></td><td>The estrogenic agent, estrone, may increase the effect of the corticosteroid, prednisolone.</td></tr><tr><td><a href="/drugs/DB00635">Prednisone</a></td><td>The estrogenic agent, estrone, may increase the effect of corticosteroid, prednisone.</td></tr><tr><td><a href="/drugs/DB00794">Primidone</a></td><td>The enzyme inducer, primidone, decreases the effect of the hormone agent, estrone.</td></tr><tr><td><a href="/drugs/DB00932">Tipranavir</a></td><td>Estropipate may increase the adverse dermatological effects (i.e. skin rash) of Tipranavir. Tipranavir may decrease the serum concentration Estropipate. Monitor for estrogen deficiency during concomitant therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>